CNS Drugs

, Volume 26, Issue 7, pp 581–600 | Cite as

Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder

A Systematic Literature Review
  • Eric Q. Wu
  • Paul Hodgkins
  • Rym Ben-Hamadi
  • Juliana Setyawan
  • Jipan Xie
  • Vanja Sikirica
  • Ella X. Du
  • Sherry Y. Yan
  • M. Haim Erder
Systematic Review



Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder that impairs the quality of life for patients and their families and is associated with considerable direct and indirect costs. Pharmacotherapies for ADHD, including stimulants and non-stimulants, are often used to treat patients with ADHD. However, the costs, effectiveness and adverse effects of these agents vary. Therefore, information regarding the cost effectiveness of different pharmacological treatments is needed to better inform payers in the allocation of limited resources.


The objectives of this study were to conduct a systematic literature review of economic evaluations of pharmacotherapies for ADHD treatments and to assess the cost effectiveness of different interventions based on the existing studies.


A systematic literature review of economic evaluations of pharmacotherapies for ADHD was conducted in MEDLINE, the National Health Services (NHS) Economic Evaluation database and EMBASE. For inclusion in this review, studies had to compare two or more ADHD interventions with at least one pharmacotherapy, assess both costs and outcomes, and be conducted between 1990 and 2011 in North America, Europe, Australia or New Zealand. Studies were excluded if they were not original research, were presented only as conference proceedings or abstracts or did not report costs associated with specific interventions. The study quality was assessed using the British Medical Journal (BMJ) health economics checklist. The literature search, data extraction and quality assessment were performed by one author and independently checked for accuracy by a second author. Discrepancies were resolved by consensus and referring to the original article. If necessary, a third reviewer was consulted.


The initial search returned 93 citations from MEDLINE, 10 from the NHS Economic Evaluation database and 377 from EMBASE. Thirteen papers met the inclusion/exclusion criteria and were included in the review. Based on the BMJ checklist, all these studies were considered to be of sufficient quality to be included in the literature review, but they varied substantially in target population, methodology and effectiveness measures. Identified pharmacotherapies were cost effective compared with no treatment, placebo, behavioural therapy or community care among children and adolescents with ADHD. Studies comparing non-stimulants with stimulants and amfetamine with methylphenidate stimulants showed inconsistent findings. A limited number of studies indicated that methylphenidate Osmotic-controlled Release Oral delivery System (OROS) was cost effective compared with short-acting methylphenidate. There were no published studies on the cost effectiveness of pharmacotherapy in the adult ADHD population, comparing stimulants, non-stimulants or adjuvant therapy. There is limited evidence on the long-term cost effectiveness of pharmacotherapies.


Among children and adolescents with ADHD, there was consistent evidence that pharmacotherapies are cost effective compared with no treatment or behavioural therapy. Adequate data are lacking to draw conclusions regarding the relative cost effectiveness of different pharmacological agents. More economic evaluations with standardized methods, such as effectiveness measures and cost components, are warranted. To better inform payers about the economic value of existing medications, future studies should also consider identifying subgroups that may have heterogeneous responses to different treatments, including analyses of recently approved treatments (e.g. lisdexamfetamine, guanfacine extended-release and clonidine extended-release) and expanding the time horizon to incorporate long-term outcomes.



Research was funded in part by the Sponsor, Shire Development LLC. The researchers from Shire Development LLC were involved in the design, collection, analysis, interpretation and fact checking of information. The content of this manuscript, the ultimate interpretation and the final decision to submit it for publication in CNS Drugs was made jointly by the authors.

Drs Hodgkins, Setyawan, Sikirica and Erder are employees of Shire Development LLC and hold stock/stock options in Shire Pharmaceuticals LLC. Shire develops and markets drugs to treat psychiatric conditions, including ADHD. Eric Q. Wu, Rym Ben-Hamadi, Jipan Xie, Ella X. Du and Sherry Y. Yan are employees of Analysis Group, Inc., a consultant for Shire Development LLC.


  1. 1.
    Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metare-gression analysis. Am J Psychiatry 2007 Jun; 164(6): 942–8PubMedCrossRefGoogle Scholar
  2. 2.
    Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: metaanalysis. Br J Psychiatry 2009 Mar; 194(3): 204–11PubMedCrossRefGoogle Scholar
  3. 3.
    Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2006 Apr; 163(4): 716–23PubMedCrossRefGoogle Scholar
  4. 4.
    Biederman J, Petty CR, Clarke A, et al. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res 2011 Feb; 45(2): 150–5PubMedCrossRefGoogle Scholar
  5. 5.
    Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008 Dec; 13(12): 1047–55PubMedGoogle Scholar
  6. 6.
    Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs 2010 Oct; 24(10): 843–66PubMedCrossRefGoogle Scholar
  7. 7.
    Maziade M, Rouleau N, Lee B, et al. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol 2009 Dec; 19(6): 709–18PubMedCrossRefGoogle Scholar
  8. 8.
    Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19(3): 215–26PubMedCrossRefGoogle Scholar
  9. 9.
    Pelham WE, Foster EM, Robb JA, et al. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambul Pediatr 2007 Jan–Feb; 7 Suppl. 1: 121–31PubMedCrossRefGoogle Scholar
  10. 10.
    US Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention deficit/hyperactivity disorder among children: United States, 2003 and 2007 [online]. Available from URL: [Accessed 2012 Jan 6]
  11. 11.
    Akinbami LJ, Liu X, Pastor PN, et al. Data from the national health interview survey, 1998–2009. NCHS Data Brief 2011 Aug; (70): 1–8PubMedGoogle Scholar
  12. 12.
    Montejano L, Sasané R, Hodgkins P, et al. Adult ADHD: prevalence of diagnosis in a US population with employer health insurance. Curr Med Res Opin 2011; 27 ppl. sn2: 5–11PubMedCrossRefGoogle Scholar
  13. 13.
    Larson K, Russ SA, Kahn RS, et al. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011 Mar; 127(3): 462–70PubMedCrossRefGoogle Scholar
  14. 14.
    Biederman J, Faraone SV, Lapey Comorbidity of diagnosis in attention-deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 1992; 1: 335–60Google Scholar
  15. 15.
    Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006 Feb; 36: 167–79PubMedCrossRefGoogle Scholar
  16. 16.
    Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010 Feb; 19(2): 83–105PubMedCrossRefGoogle Scholar
  17. 17.
    McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44(6): 530–8PubMedCrossRefGoogle Scholar
  18. 18.
    Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004 Nov; 114(5):e541–7PubMedCrossRefGoogle Scholar
  19. 19.
    Szatmari P, Offord DR, Boyle MH. Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry 1989; 30: 219–30PubMedCrossRefGoogle Scholar
  20. 20.
    Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005 Feb; 90 Suppl. 1: i2–7PubMedCrossRefGoogle Scholar
  21. 21.
    Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 2005 Jun; 47(6): 565–72PubMedCrossRefGoogle Scholar
  22. 22.
    Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005 Dec; 10(12 Suppl. 20): 26–34PubMedGoogle Scholar
  23. 23.
    Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011 Nov; 128(5): 1007–22PubMedCrossRefGoogle Scholar
  24. 24.
    Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder: first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl. 1: i7–30PubMedGoogle Scholar
  25. 25.
    National Institute for Health and Clinical Excellence (NICE). Diagnosis and management of ADHD in children, young people and adults [online]. London: UK National Collaborating Centre for Mental Health, 2008. Available from URL: [Accessed 2011 Dec 15]
  26. 26.
    Verma R, Balhara YPS, Mathur S. Management of attention-deficit hyperactivity disorder. J Pediatr Neurosci 2011 Jan; 6(1): 13–8PubMedGoogle Scholar
  27. 27.
    Rösler M, Casas M, Konofal E, et al. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 2010 Aug; 11:684–98PubMedCrossRefGoogle Scholar
  28. 28.
    Brams M, Moon E, Pucci M, et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin 2010 Aug; 26(8): 1809–25PubMedCrossRefGoogle Scholar
  29. 29.
    European Medicines Agency. Summary assessment report of the Pharmacovigilance Working Party (PhVWP): November 2011 plenary meeting [online]. Available from URL: [Accessed 2011 Dec 15]
  30. 30.
    Nutt DJ, Fone Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007 Jan; 21(1): 10–41PubMedCrossRefGoogle Scholar
  31. 31.
    Retz W, Retz-Junginger P, Thome J, et al. Pharmacological treatment of adult ADHD in Europe. World J Biol Psychiatry 2011 Sept; 12 Suppl. 1: 89–94PubMedGoogle Scholar
  32. 32.
    Intuniv® [package insert]. Wayne (PA): Shire US, Inc., 2011 JunGoogle Scholar
  33. 33.
    Kapvay® [package insert]. Atlanta (GA): Shionogi Pharma, Inc., 2010 SepGoogle Scholar
  34. 34.
    Fisher M, Newby RF. Assessment of stimulant response in ADHD children using a refined multimethod clinical protocol. J Clin Child Psychol 1991; 20(3): 232–44CrossRefGoogle Scholar
  35. 35.
    Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001 Jun; 107(6): E105PubMedCrossRefGoogle Scholar
  36. 36.
    Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 109(3): E39PubMedCrossRefGoogle Scholar
  37. 37.
    Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108(5): E83PubMedCrossRefGoogle Scholar
  38. 38.
    Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7PubMedCrossRefGoogle Scholar
  39. 39.
    Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006 Jul; 149(1): 112–9PubMedCrossRefGoogle Scholar
  40. 40.
    Scheffler RM, Brown TT, Fulton BD, et al. Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 2009 May; 123(5): 1273–9PubMedCrossRefGoogle Scholar
  41. 41.
    Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005 Feb; 21(2): 195–205PubMedCrossRefGoogle Scholar
  42. 42.
    Hodgkins P, Montejano L, Sasané R, et al. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord 2011; 13(2): pii: m01030Google Scholar
  43. 43.
    De Ridder A, De Graeve D. Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Investig 2006; 26(2): 75–90PubMedCrossRefGoogle Scholar
  44. 44.
    Hakkaart-van Roijen L, Zwirs BW, Bouwmans C, et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2007 Aug; 16(5): 316–26PubMedCrossRefGoogle Scholar
  45. 45.
    Ray GT, Croen LA, Habel LA. Mothers of children diagnosed with attention-deficit/hyperactivity disorder: health conditions and medical care utilization in periods before and after birth of the child. Med Care 2009 Jan; 47(1): 105–14PubMedCrossRefGoogle Scholar
  46. 46.
    Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003 Dec; 42(12): 1415–23PubMedCrossRefGoogle Scholar
  47. 47.
    De Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008 Dec; 65(12): 835–42PubMedCrossRefGoogle Scholar
  48. 48.
    Forness SR, Kavale KA. Impact of ADHD on school systems. In: Jensen PS, Cooper JR, editors. Attention deficit hyperactivity disorder. Kingston (NJ): Civic Research Institute, 2002; 1–30Google Scholar
  49. 49.
    Fletcher J, Wolfe B. Long-term consequences of childhood ADHD on criminal activities. J Ment Health Policy Econ 2009 Sep; 12(3): 119–38PubMedGoogle Scholar
  50. 50.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009 Jul; 6: e1000100PubMedCrossRefGoogle Scholar
  51. 51.
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug 3; 313(7052): 275–83PubMedCrossRefGoogle Scholar
  52. 52.
    Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econ 2002; 3(2): 131–6PubMedCrossRefGoogle Scholar
  53. 53.
    Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepi-demiol Drug Saf 2001 Mar-Apr; 10(2): 85–94CrossRefGoogle Scholar
  54. 54.
    Narayan S, Hay J. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res 2004 Dec; 4(6): 625–34PubMedCrossRefGoogle Scholar
  55. 55.
    Zupancic JA, Miller A, Raina P, et al. Part 3: economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Raina P, editors. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 1998Google Scholar
  56. 56.
    Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001 Nov; 23(11): 1904–21PubMedCrossRefGoogle Scholar
  57. 57.
    Vanoverbeke N, Annemans L, Ingham M, et al. A cost analysis of the management of attention-deficit/hyperactivity disorder (ADHD) in children in the UK. JME 2003; 6(1–4): 79–94Google Scholar
  58. 58.
    Donnelly M, Haby MM, Carter R, et al. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2004 Aug; 38(8): 592–601PubMedCrossRefGoogle Scholar
  59. 59.
    Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs 2008; 22(2): 157–70PubMedCrossRefGoogle Scholar
  60. 60.
    Cottrell S, Tilden D, Robinson P, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health 2008 May-Jun; 11(3): 376–88PubMedCrossRefGoogle Scholar
  61. 61.
    Hong J, Dilla T, Arellano J. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry 2009 Apr 1; 9: 15PubMedCrossRefGoogle Scholar
  62. 62.
    King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006 Jul; 10(23): iii–iv, xiii–146Google Scholar
  63. 63.
    Lord J, Paisley S. The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood. London: National Institute for Clinical Excellence, 2000Google Scholar
  64. 64.
    Foster EM, Jensen PS, Schlander M, et al. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res 2007 Feb; 42(1 Pt 1): 165–82PubMedCrossRefGoogle Scholar
  65. 65.
    Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 2005 Sep; 162(9): 1628–36PubMedCrossRefGoogle Scholar
  66. 66.
    Oanda®. Currency exchange rate [online]. Available from URL: [Accessed 2011 Nov 14]
  67. 67.
    Secnik K, Matza LS, Cottrell S, et al. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom. Med Decis Making 2005 Jan–Feb; 25(1): 56–70PubMedCrossRefGoogle Scholar
  68. 68.
    Boles M, Lynch FL, DeBar LL. Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. J Child Adolesc Psychopharmacol 2001; 11(1): 43–52PubMedCrossRefGoogle Scholar
  69. 69.
    Sawyer MG, Kosky RJ, Graetz BW, et al. The National Survey of Mental Health and Wellbeing: the child and adolescent component. Aust N Z J Psychiatry 2000 Apr; 34(2): 214–20PubMedCrossRefGoogle Scholar
  70. 70.
    Lloyd A, Hodgkins P, Dewilde S, et al. Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. Int J Technol Assess Health Care 2011 Jul; 27(3): 215–23PubMedCrossRefGoogle Scholar
  71. 71.
    Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006 Dec; 15(8): 476–95PubMedCrossRefGoogle Scholar
  72. 72.
    Erder M, Chen K, Wu EQ, et al. PMH37 The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents [abstract]. Value in Health 2011 May; 14(3): A192CrossRefGoogle Scholar
  73. 73.
    Sikirika V, Erder MH, Xie J, et al. Cost-effectiveness of guanfacine extended release as an adjunctive therapy to a psychostimulant compared to psychostimulant monotherapy for the treatment of attention deficit/hyperactivity disorder in children and adolescents. Value in Health 2011 Nov; 14(7): A401–2CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Eric Q. Wu
    • 1
  • Paul Hodgkins
    • 2
  • Rym Ben-Hamadi
    • 1
  • Juliana Setyawan
    • 2
  • Jipan Xie
    • 1
  • Vanja Sikirica
    • 2
  • Ella X. Du
    • 1
  • Sherry Y. Yan
    • 1
  • M. Haim Erder
    • 2
  1. 1.Analysis Group, Inc.BostonUSA
  2. 2.Shire Development LLC.WayneUSA

Personalised recommendations